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Valorization addendum 
In this addendum, we will attempt to translate the findings of this thesis in terms of 
‘knowledge valorization’. Knowledge valorization of research refers to the process of 
creating value from knowledge, by making it available for social and or societal utilization. 
Diseases associated with chronic pain are increasing in prevalence and are a global cause 
of disability in both the developed and developing countries.1,2 Chronic pain is associated 
with a lowered quality of life (QoL),3,4 and can have an important impact upon mood, 
cognition and emotional functioning,5 leading to restrictions upon functioning during 
daily activities and work.6 Amongst all causes of chronic pain, neuropathic pain is 
particularly cumbersome.7 Additionally, neuropathic pain is widely recognized as one of 
the most difficult pain syndromes to manage.8 
One of the most common causes of neuropathic pain is polyneuropathy, which is 
typically characterized by symmetrical sensory symptoms in the distal parts of the limbs.9 
The overall prevalence of polyneuropathy in the general population ranges from 1 to 3% 
and rises to 7% in the elderly.10 In developing countries the prevalence is lower, possibly 
explained by a smaller proportion of elderly and by differences in the prevalence of 
polyneuropathy risk factors.10 In the last decades, the prevalence of polyneuropathy is 
increasing due to an aging population and the increasing prevalence of risk factors like 
diabetes mellitus (DM) and obesity.10,11 The prevalence of neuropathic pain in diabetic 
polyneuropathy in people with DM ranges from 6 to 34%,12 and this symptom is its most 
costly complication.13–15Other causes of polyneuropathy include toxic agents, such as 
chemotherapeutic drugs, nutritional deficiencies, autoimmune-mediated causes and 
hereditary factors.9,10 Polyneuropathy is furthermore reported to be present in 13–66 % 
of chronic alcoholics,16,17 and in up to 50% an underlying cause cannot be identified.18 
In this chapter, we will address the social and economic relevance of our research 
results. For this purpose, will we first present the impact of pain on patients with 
polyneuropathy and its impact on society. 
What is the impact of pain on patients with polyneuropathy? 
Painful polyneuropathy has a huge impact on patients. Despite other symptoms like 
paresthesias and dysesthesias, pain is a primary indicator for worsening QoL and 
diminished overall wellbeing in patients with polyneuropathy.19 A study regarding PDPN 
patients showed that PDPN patients had a significantly worse QoL compared with DM 
patients without pain and DM patients with non-neuropathic pain.20 QoL is inversely 
associated with neuropathic pain severity and pain duration in patients with painful 
polyneuropathy.21 The etiology of polyneuropathy does not influence levels of 
neuropathic pain-related compromise of QoL.19  
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Painful polyneuropathy is a disabling disease and is related to poor sleep and 
symptoms of anxiety and depression.19,20,22 Pain intensity in polyneuropathy patients is 
positively associated with disability.22 Pain in these patients can considerably affect daily 
life by reducing the ability to walk and perform general everyday activities.12 It can have 
a major impact on recreational activities, work, social activities, mobility, and experienced 
stress.23,24 Studies have demonstrated that PDPN patients score 4.8 for overall pain 
interference on the brief pain inventory (BPI) (0 is no interference and 10 is complete 
interference).12 The subscales for general activity and walking ability were generally most 
affected.12,25 However, the subscales for sleep, mood and enjoyment of life were almost 
equally highly impaired.25 Painful polyneuropathy is often associated with sleep 
disturbance due to the fact that most patients have nocturnal pain. Studies of PDPN 
patients report that 72–96% of the patients are moderately to severely affected in their 
sleep.,26 Higher pain severity is significantly correlated with higher interference of 
sleep.12,27 In addition, studies have shown that 24.5–72.1% of PDPN patients have 
symptoms of depression and/or anxiety pain,12 and PDPN has been shown to be a greater 
determinant of depression than other DM-related complications and comorbidities.28 
Despite this great patient burden of pain caused by polyneuropathy, pain in 
polyneuropathy patients is often not well recognized and treated.29 The effectiveness of 
pharmacological treatment is often minor and frequently accompanied by unacceptable 
side effects.30 In addition, patients with painful polyneuropathy are more likely to have 
medication incompliance, like inappropriate polypharmacy and misuse of prescribed 
medications.19 Many patients require pain treatment with more than one medication, 
which increases the risk of additional adverse events and incorrect use of medication.31 
Furthermore, concomitant medication use is high in these patients. For instance, a 
patient survey has shown that 43% of PDPN patients received prescription medications 
for sleep disturbance, anxiety and/or depression.32  
What is the impact of pain in patients with polyneuropathy on 
society? 
Painful polyneuropathy is associated with greater health care utilization in 
comparison to not painful polyneuropathy. Examples of health care utilization are 
outpatient clinic visitations, overnight hospitalizations, and the use of a nursing or 
rehabilitation home.19 To give an example, the resource use of PDPN patients results in 
mean annual per patient UK health care costs of €2,963.33 Of these costs, 41% is 
accounted for inpatient care. The annual costs found in the UK were comparable to those 
found in Spain.34 The costs of medications account for approximately 30% of the 
healthcare costs.33,34 In addition, in patients with painful polyneuropathy a large number 
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of hospital admissions are related to medication side effects.19 Higher pain severity in 
PDPN patients is significantly correlated with higher resource use and direct costs.25,33,35 
Painful polyneuropathy can result in additional costs for society because it can lead 
to absence from work or reduced functionality at work.12 In a European study regarding 
634 PDPN patients, disturbance in employment status resulted in productivity losses of 
€10,484 per patient per year.36 PDPN severity was significantly associated with lost 
productivity, which was higher with increasing severity, and resulted in significantly 
higher costs. Productivity losses were similar among the countries France, Germany, Italy, 
and the UK, and were primarily driven by presenteism (impairment while working). In a 
UK study, 35% of the PDPN patients reported disruption in employment status due to 
pain, and 59% of the working patients was less productive at work.25  
Generally, neuropathic pain reduction, as a result of treatment, is related to 
improvement in QoL.37  
The humanistic and economic burden from painful polyneuropathy appears to be 
higher with increasing pain severity. Therefore, it is of particular importance to recognize 
painful polyneuropathy in patients and to optimize pain treatment.19 Emerging 
neuromodulation options for painful polyneuropathy are spinal cord stimulation (SCS) 
and dorsal root ganglion stimulation (DRGS),38–42 being a last resort treatment method 
when conventional therapies have failed.38,39,43,44 SCS has been shown to be effective in 
PDPN.38,45–49 Treatment with SCS has also been shown to be effective in intractable 
painful polyneuropathy due to other causes, like HIV infection and chemotherapy.43,44 
Slangen et al. performed an economic evaluation comparing SCS with best medical 
treatment (BMT) in PDPN patients.50 Incremental cost-effectiveness ratios were based 
on: 1) societal costs and quality-adjusted life years, and 2) direct health care costs and 
the number of successfully treated patients, respectively. Although SCS was considerably 
more effective compared with BMT, Slangen et al. concluded from the results of their 
study that SCS was not cost effective compared with BMT at the 12-month follow-up, 
mainly because of the substantial initial investment costs of SCS. However, secondary 
analyses showed that the incremental cost effectiveness ratios decreased considerably 
when correcting for baseline differences in costs, and extending the depreciation period 
of the SCS material to 4 years.50 
There are limits to the effectiveness of conventional SCS in the treatment of painful 
polyneuropathy. To illustrate, this treatment is known to provide approximately 50% pain 
reduction to only 60% of PDPN patients.38,45,46,49 Forty percent of the patients is therefore 
not responding to this therapy. Furthermore, the analgesic effect of SCS treatment is 
known to decrease over time,51 and SCS is often unable to cover the pain in the so-called 
“difficult-to-reach areas”, like the feet.52,53 In view of these limitations, optimization of 
neurostimulation therapy is needed and the new location of stimulation at the DRG 
(dorsal root ganglion stimulation, DRGS) is shown to be a promising new option for 
treatment of PDPN. Early findings from one retrospective case series in painful diabetic 
polyneuropathy patients suggested that DRGS is an effective neuromodulation modality 
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to improve painful symptoms.41 Furthermore, the results of another small retrospective 
case series suggest that DRGS may be an effective treatment option for painful hereditary 
and idiopathic axonal polyneuropathy.42 Except the fact that DRGS seems provide a better 
coverage of the difficult-to-reach areas, it offers several other potential benefits over SCS 
systems like lack of positional and movement effects on stimulation and reduced 
migration rate, because of better lead stability.52,54 Additionally, as the anatomical 
location of the DRG offers a closer proximity to the electrodes compared to the spinal 
cord and its dorsal columns, reduced power is required.52,54 Nevertheless, more clinical 
evidence is warranted to confirm the efficacy of this treatment for painful 
polyneuropathy. 
What is the social and economic relevance of our research 
results?  
If DRGS can effectively reduce pain in intractable painful polyneuropathy, not only the 
individual patient would benefit, but also the burden on medical care systems would be 
lessened. Hence, the research described in this thesis focused upon establishment and 
optimization of treatment with DRGS in painful polyneuropathy patients, and further 
understanding the underlying mechanism.  
A major conclusion of the results in this thesis is that DRGS seems to be established 
for pain relief in painful polyneuropathy in humans and in a PDPN animal model (Chapter 
2, 3 and 4). Our results furthermore showed that effectiveness for pain relief is similar 
with DRGS and SCS in PDPN animals (Chapter 4).  
To further optimize effectiveness of DRGS in the treatment of pain in painful 
polyneuropathy, we explored and compared the effectiveness of different DRGS 
frequencies and concluded that DRGS is equally effective when applied at low-, mid- and 
high-frequency, at least in an animal model of PDPN (Chapter 5). Nevertheless, as low-
frequency DRGS resulted in a delayed wash-out effect, this frequency might be the most 
optimal setting in DRGS for PDPN as compared to mid frequency and high frequency. 
Moreover, the use of LF-DRGS will lead to a prolonged battery life as compared to MF- 
and HF-DRGS and thus has important consequences for costs-effectiveness of this 
treatment.  
Lastly, understanding of the working mechanism underlying SCS- and DRGS-induced 
pain relief may enable optimization of treatment and result in better treatment 
outcomes. In relation to this, another key finding of this thesis is that DRGS, in contrast 
to SCS, does not induce γ-aminobutyric acid (GABA) release in spinal dorsal horn of PDPN 
rats (Chapter 6). With this observation we suggest that the mechanism underlying DRGS-
induced pain relief is different from that of dorsal column SCS and the modulation of a 
GABA mediated “Gate Control” in the DRG, functioning as a prime Gate of nociception, is 
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suggested. Further research is warranted to elucidate the mechanism underlying DRGS 
in pain relief. 
To conclude, painful polyneuropathy patients are subjected to a significant 
physiological, psychological and functional burden. It is essential to raise awareness of 
painful polyneuropathy and to encourage healthcare providers to better identify patients 
with painful polyneuropathy to, as this condition deeply affects patients’s quality of life 
and disability. If new treatment options like DRGS can effectively reduce pain in painful 
polyneuropathy patient, the humanistic and economic burden of painful polyneuropathy 
would be lessened. With the research of this thesis, we established and tried to optimize 
DRGS in the treatment of painful polyneuropathy patients. Furthermore, our research let 
us a little bit closer to understanding the underlying mechanism of DRGS, hopefully 
enabling future optimization of treatment, resulting in better outcomes. 
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